Images
The newspaper La Razón has interviewed IRB Barcelona researcher Meritxel Teixidó in the context of the grant award ceremony of the ”la Caixa” Foundation, which was held on 16 September.Teixidó has received a CaixaImpulse grant to work towards the preclinical development of one of the compounds that shows the greatest therapeutic potential for a given type of pediatric brain cancer. “We know that drugs are necessary to treat these patients, but they can´t reach the brain in sufficient amounts. Greater amounts could be administered to ensure that the correct amount reaches the brain but this would cause many side effects,” explains Teixidó, who goes on to say that, “the idea is to perform assays on mice to test whether our peptides can carry drugs into the brain in these animals”.
Link to La Razón
About IRB Barcelona
The Institute for Research in Biomedicine (IRB Barcelona) pursues a society free of disease. To this end, it conducts multidisciplinary research of excellence to cure cancer and other diseases linked to ageing. It establishes technology transfer agreements with the pharmaceutical industry and major hospitals to bring research results closer to society, and organises a range of science outreach activities to engage the public in an open dialogue. IRB Barcelona is an international centre that hosts 400 researchers and more than 30 nationalities. Recognised as a Severo Ochoa Centre of Excellence since 2011, IRB Barcelona is a CERCA centre and member of the Barcelona Institute of Science and Technology (BIST).
